Good SpaceX earnings could help Rocket Lab lead the new-space sector higher with a rally as violent as its capitulation. Rocket Lab is the sector leader outside SpaceX; its RSI is extremely oversold, the lower Bollinger band is overstretched and MACD's negative divergence is subsiding. Three upside gaps lie at $55.25-59.18, $64.22-65.71 and $73.11-74.76. The highest should fill before year-end, though the exact date is hard to predict. x.com  x.com 

Rocket Lab's growing Space Systems business positions it to provide more than launches for the space economy. It generated $189.5M in Q2, 81% of revenue; if its pending Iridium acquisition closes, it would gain a global satellite communications network. At about $51, this is one of the most compelling long-term opportunities in the space sector over 3-5 years, provided it keeps executing. Neutron's launch has slipped to 2027, and execution risks remain. x.com  x.com  x.com 

Rocket Lab's delayed Neutron first flight pushes out a key part of its planned launch capacity. Flight one has moved to 2027, at least 1.5 years later than the previously indicated timing; the lack of clearer guidance is frustrating. The stock could fall 50% if it breaks key support, though that downside is conditional. x.com  x.com  x.com 

Rocket Lab's Neutron delay looks like a manufacturing issue, not a flawed design. Rocket Lab says it identified and mitigated dome voids, but this second setback delays launch revenue; first flight could slip to mid-2027 or later if testing finds more issues. Space Systems is about 81% of revenue and backlog is around $2.4B, sustaining the business as Neutron develops. Rocket Lab could still become a megacap over the next decade. x.com 

Rocket Lab's rising Electron output and cost competitiveness could unlock a big European opportunity. COO Frank Klein says next year's production will exceed twice 2024's 15 rockets and argues buyers would not pay two or three times as much merely for a German-built rocket. He says Rocket Lab is discussing launch capacity with Germany and ESA, while Germany plans $41.1 billion in defense-space spending over five years. 2027 looks like a huge year for Rocket Lab. x.com 

Rocket Lab could face a difficult 9-12 months because much of the space industry's future is already priced into equity valuations, even as its business and backlog grow. A monthly close below the $61 21-month EMA would raise the risk that the uptrend has ended and shift attention toward $35-45 for a better long-term entry; holding $61 preserves a more constructive reading. The company could still trade considerably higher over a longer horizon. x.com 

Rocket Lab's existing Space Systems business makes Neutron upside optionality rather than the whole investment case. Space Systems supplied $189.5M, about 81% of Q2's record $234M revenue, alongside Electron launches, defense work, satellite manufacturing and components. Delaying Neutron's first launch to 2027 hurts a major catalyst and raises execution questions, but rushing a rocket failure would be costlier. x.com 

Rocket Lab's after-hours selloff on a record quarter is a buying opportunity because it is becoming a space prime, one of only two full-stack space companies alongside SpaceX. Revenue hit a record $234M, up 62%, backlog a record $2.36B, up 137%, with more than $1B of Q3 contracts signed and $2.4B of cash. On VICTUS HAZE it launched in 16h42m against a 24-hour window. CEO Peter Beck said Neutron delay coverage is exaggerated. Rating stays Overweight with a $130 target. x.com  x.com  x.com 

Repeated Neutron delays undermine the premium on Rocket Lab stock when execution keeps slipping. The company does not live or die by Neutron, but 50x sales was unjustified; even at 26x 2027 sales, a legitimate price suggests another 50% decline. x.com  x.com 

Rocket Lab's Electron performance supports the case that it can scale Neutron faster than Terran-R, MLV and Stoke once it flies, as it has shown before. Retail patience with Neutron timelines is wearing thin, so Q3 earnings need good news, such as Archimedes engine qualification or the Stage 1 tank passing hydro and cryo tests; without either, investors will understandably be unhappy. x.com